Cipla Ltd.

View in App
966.85 +2.60 ▲0.3%

02 June 2023, 04:01:00 PM
Volume: 135,984

Company Profile

View details >>
Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.cipla.com
Market Cap 77,917.34 Cr.
Enterprise Value(EV) 76,873.08 Cr. 2023-03
Financial Indicators
Earnings per share (EPS) 34.71 Trailing Twelve Months Ending 2023-03
Price-Earning Ratio (PE) 27.85 Trailing Twelve Months Ending 2023-03
Industry PE 33.43 Trailing Twelve Months Ending 2023-03
Book Value / Share 289.98 Trailing Twelve Months Ending 2023-03
Price to Book Value 3.33 Calculated using Price: 966.85
Dividend Yield 0.88 Period Ending 2022-03
No. of Shares Subscribed 80.72 Cr. 807,224,436 Shares
FaceValue 2
About Cipla Ltd.
The company is in the business of manufacturing, developing, and marketing wide range of branded and generic formulations and Active Pharmaceutical Ingredients (APIs). The company has its wide network of manufacturing, trading and other incidental operations in India and International markets.

Cipla Ltd. Delivery

View details >>
Delivered Qty
Traded Qty

Cipla Ltd. Performance

View details >>
1 Day
+0.27%
1 Week
+1.67%
1 Month
+5.53%
3 Month
+9.04%
6 Month
-13.10%
1 Year
-2.08%
2 Year
+1.29%
5 Year
+84.74%
10 Year
+160.99%

Cipla Ltd. Fundamental Ratios

View details >>
9 years 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03 2021-03 2022-03
Return on Equity (%) 14.89 12.10 12.61 8.72 10.65 10.37 10.09 14.13 13.10
Return on Capital Employed (%) 19.05 15.33 13.24 8.28 10.20 11.94 12.53 17.85 17.24
Return on Assets (%) 10.49 7.85 7.28 4.97 6.52 6.50 6.56 9.95 9.94

Cipla Ltd. Balance Sheet

View details >>
Particulars 10 years 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2023-03* Rs. Cr.
Shh. Funds 10,050 10,801 11,516 12,544 14,229 15,012 15,763 18,327 20,842 23,408
Non Curr. Liab. 2,028 2,418 1,407 4,513 4,259 4,646 2,972 1,660 622 184
Curr. Liab. 2,564 3,881 7,776 3,374 3,832 3,772 4,393 4,591 4,913 5,110
Minority Int. 50 180 350 438 352 332 294 259 276 306
Equity & Liab. 14,692 17,281 21,049 20,869 22,673 23,762 23,423 24,837 26,652 29,007
Non Curr. Assets 9,040 9,689 12,208 12,064 11,859 11,335 11,717 11,628 11,925 11,732
Curr. Assets 5,652 7,591 8,841 8,736 10,814 12,425 11,704 13,181 14,711 17,275
Misc. Exp. not W/O
Total Assets 14,692 17,281 21,049 20,869 22,673 23,762 23,423 24,837 26,652 29,007

Cipla Ltd. Profit and Loss

View details >>
Particulars 10 years 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2023-03 Rs. Cr. TTM
Net Sales 10,173 11,345 13,595 14,394 15,156 16,362 17,132 19,160 21,763 22,753
Other Income 265 166 208 229 358 477 369 270 322 475
Total Income 10,439 11,511 13,803 14,623 15,513 16,839 17,501 19,429 22,085 23,229
Total Expenditure -8,040 -9,184 -11,115 -11,919 -12,329 -13,265 -13,951 -14,911 -17,251 -17,726
PBIDT 2,398 2,327 2,688 2,704 3,184 3,574 3,550 4,518 4,834 5,502
Interest -146 -168 -207 -159 -114 -168 -197 -161 -106 -110
Depreciation -373 -505 -754 -1,323 -1,323 -1,326 -1,175 -1,068 -1,052 -1,172
Taxation -463 -400 -332 -180 -250 -570 -631 -889 -934 -1,203
Exceptional Items -78 -182 -182
PAT 1,417 1,254 1,395 1,042 1,419 1,510 1,547 2,401 2,559 2,835
Minority Interest -16 -48 -23 -29 -6 35 47 16 -30 -31
Share Associate -12 -25 -12 -7 -3 -17 -47 -13 -13 -3
Other Related Items
Consolidated Net Profit 1,388 1,181 1,360 1,006 1,411 1,528 1,547 2,405 2,517 2,802
Adjusted EPS 17 15 17 13 18 19 19 30 31 35

Cipla Ltd. Cash Flow

View details >>
Particulars 10 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr.
Cash Fr. Operatn. 1,398 1,563 1,173 1,741 2,382 1,463 1,691 3,068 3,755 3,326
Cash Fr. Inv. -2,063 -1,250 -941 -4,523 -1,310 -854 -1,669 104 -2,387 -1,872
Cash Fr. Finan. 718 -266 165 3,104 -1,326 -385 -349 -2,949 -1,240 -1,600
Net Change 53 48 397 322 -254 223 -326 224 129 -146
Cash & Cash Eqvt 143 176 564 858 610 853 508 742 790 658

Cipla Ltd. Shareholding Pattern

View details >>
9 Qtrs 2021-03 (%) 2021-06 (%) 2021-09 (%) 2021-12 (%) 2022-03 (%) 2022-06 (%) 2022-09 (%) 2022-12 (%) 2023-03 (%)
Promoter 36.73 36.72 36.12 36.11 33.63 33.61 33.61 33.61 33.55
Public 63.27 63.28 63.88 63.89 66.37 66.39 66.39 66.39 66.45
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Cipla Ltd. Announcements

View details >>
Wed, 31 May 2023
Announcement under Regulation 30 (LODR)-Updates on Acquisition
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 and further to our intimation dated 14th March 2023 this is to inform you that the proposed sale of stake held in Cipla Quality Chemical Industries Limited(CQCIL) step-down subsidiary of the Company in Uganda is expected to be completed on or before 31st July 2023. This timeline is subject to receipt of regulatory approvals and satisfaction of conditions as agreed in the Share Purchase Agreement (SPA) signed between the parties and may be further extended as mutually agreed between the parties.
Tue, 30 May 2023
Compliances-Reg.24(A)-Annual Secretarial Compliance
Pursuant to Regulation 24A of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirement) Regulations 2015 please find enclosed the Annual Secretarial Compliance Report for the financial year 2022-23 issued by BNP & Associates Practising Company Secretaries.
Mon, 29 May 2023
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) and other applicable regulations of SEBI Listing Regulations we would like to inform you that Registrar and Transfer Agent of Company M/s. KFin Technologies Limited has received intimation for loss of share certificate and request for issuance of duplicate share certificate from the following shareholder

Cipla Ltd. Technical Scans

View details >>
Fri, 02 Jun 2023
High Delivery Percentage High Delivery Percentage
Higher Delivery Quantity Higher Delivery Quantity
Higher Delivery Quantity and Percentage Higher Delivery Quantity and Percentage
Higher Trade Quantity Higher Trade Quantity
Higher Trade and Delivery Quantity Higher Trade and Delivery Quantity

Cipla Ltd. Related Stocks

View details >>
  • SALES
Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 239,777.54 999.35 +1.2%
Divi's Laboratories Ltd. 93,340.08 3,539.90 +0.4%
Dr. Reddy's Laboratories Ltd. 76,753.53 4,610.45 +1.3%
Apollo Hospitals Enterprise Ltd. 71,422.15 4,957.90 +2.9%
Torrent Pharmaceuticals Ltd. 60,134.99 1,774.00 -0.1%
Mankind Pharma Ltd. 58,728.27 1,466.05 +4.9%
Zydus Lifesciences Ltd. 52,487.85 519.40 +1.2%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 28.30 999.35 +1.2%
Divi's Laboratories Ltd. Consolidated 2023-03 51.54 3,539.90 +0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 17.03 4,610.45 +1.3%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 87.03 4,957.90 +2.9%
Torrent Pharmaceuticals Ltd. Consolidated 2023-03 48.23 1,774.00 -0.1%
Mankind Pharma Ltd. Standalone 2022-03 43.99 1,466.05 +4.9%
Zydus Lifesciences Ltd. Consolidated 2023-03 26.82 519.40 +1.2%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 4.28 999.35 +1.2%
Divi's Laboratories Ltd. Consolidated 2023-03 7.36 3,539.90 +0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 3.30 4,610.45 +1.3%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 11.52 4,957.90 +2.9%
Torrent Pharmaceuticals Ltd. Consolidated 2023-03 9.69 1,774.00 -0.1%
Mankind Pharma Ltd. Standalone 2022-03 5.65 1,466.05 +4.9%
Zydus Lifesciences Ltd. Consolidated 2023-03 3.00 519.40 +1.2%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 0.03 999.35 +1.2%
Divi's Laboratories Ltd. Consolidated 2022-03 0.00 3,539.90 +0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 0.18 4,610.45 +1.3%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 0.47 4,957.90 +2.9%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 0.68 1,774.00 -0.1%
Mankind Pharma Ltd. Standalone 2022-03 0.14 1,466.05 +4.9%
Zydus Lifesciences Ltd. Consolidated 2022-03 0.25 519.40 +1.2%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 7.21 999.35 +1.2%
Divi's Laboratories Ltd. Consolidated 2022-03 28.16 3,539.90 +0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 11.93 4,610.45 +1.3%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 21.60 4,957.90 +2.9%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 13.18 1,774.00 -0.1%
Mankind Pharma Ltd. Standalone 2022-03 26.72 1,466.05 +4.9%
Zydus Lifesciences Ltd. Consolidated 2022-03 15.51 519.40 +1.2%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 7.21 999.35 +1.2%
Divi's Laboratories Ltd. Consolidated 2022-03 28.16 3,539.90 +0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 11.93 4,610.45 +1.3%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 21.60 4,957.90 +2.9%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 13.18 1,774.00 -0.1%
Mankind Pharma Ltd. Standalone 2022-03 26.72 1,466.05 +4.9%
Zydus Lifesciences Ltd. Consolidated 2022-03 15.51 519.40 +1.2%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 38,654.49 999.35 +1.2%
Divi's Laboratories Ltd. Consolidated 2022-03 8,959.83 3,539.90 +0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 21,545.20 4,610.45 +1.3%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 14,662.60 4,957.90 +2.9%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 8,508.04 1,774.00 -0.1%
Mankind Pharma Ltd. Standalone 2022-03 7,781.56 1,466.05 +4.9%
Zydus Lifesciences Ltd. Consolidated 2022-03 15,265.20 519.40 +1.2%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 3,405.82 999.35 +1.2%
Divi's Laboratories Ltd. Consolidated 2022-03 2,960.45 3,539.90 +0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 2,182.50 4,610.45 +1.3%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 1,101.10 4,957.90 +2.9%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 777.18 1,774.00 -0.1%
Mankind Pharma Ltd. Standalone 2022-03 1,452.96 1,466.05 +4.9%
Zydus Lifesciences Ltd. Consolidated 2022-03 2,326.40 519.40 +1.2%

Cipla Ltd. FAQ's

What is Cipla share price?
Can I buy Cipla shares now?
What is the Dividend Yield of Cipla?
What is the Market Cap of Cipla?
What are the key metrics to analyse Cipla?
What is the 52 Week High and Low of Cipla?
What is the trend of Cipla share price?